Source link : https://www.newshealth.biz/health-news/fda-approves-bimekizumab-for-three-rheumatologic-conditions/
The US Food and Drug Administration has approved bimekizumab-bkzx (Bimzelx; UCB) for adult patients with active psoriatic arthritis (PsA), active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS). The drug, an interleukin (IL)-17A and IL-17F inhibitor, was first approved in October 2023 for treatment of moderate to severe plaque […]
Author : News Health
Publish date : 2024-09-23 16:59:49
Copyright for syndicated content belongs to the linked Source.
inHealth